Antoine Hollebecque, MD
The potent FGFR1-3 inhibitor pemigatinib (INCB054828) showed preliminary efficacy and safety signals in the phase II FIGHT-202 trial (NCT02924376) of patients with previously treated advanced, metastatic or surgically unresectable cholangiocarcinoma. Data from the first 47 patients with FGFR2
translocations enrolled in cohort A were presented at the 2018 ESMO Congress.
Hollebecque A, Borad M, Sahai V, et al. Interim results of FIGHT-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations [published online ahead of print October 23, 2018]. Ann Oncol. doi: 10.1093/annonc/mdy282.139.
... to read the full story